Urology

Researchers at Weill Cornell Medicine have led a phase 1 trial of a new drug that delivers potent radiation therapy directly and specifically to cancer cells in patients with advanced prostate cancer. The clinical trial showed that the “radiopharmaceutical” was well tolerated and demonstrated promising antitumor activity.

An easy-to-use device for infant circumcision has proved to be safe in an international randomized controlled clinical trial led by Weill Cornell Medicine physician-scientists. The results suggest that the device could boost efforts to increase circumcision rates and prevent HIV in low-resource settings where early infant circumcision is not widespread. 

New research led by investigators from Weill Cornell Medicine, Fred Hutchinson Cancer Center, University Hospitals Cleveland and Case Western Reserve University found that prostate cancer screening with the prostate specific antigen (PSA) blood test has remarkably favorable tradeoffs.

Dr. Larissa V. Rodríguez, a distinguished physician-scientist and urologic surgeon who specializes in female pelvic medicine and reconstructive surgery, has been named chair of the Department of Urology at Weill Cornell Medicine and urologist-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center

Molecular characteristics detected in prostate cancers can provide clues that help predict how the disease will progress, according to new research from investigators at Weill Cornell Medicine and NewYork-Presbyterian.

Conventional wisdom suggests that a high level of the protein prostate specific antigen (PSA) in men with prostate cancer means a poor prognosis. However, this may not always be the case in men with a particular subtype of prostate cancer, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian researchers.

A surgically implanted device used to regulate bladder and bowel control often requires additional operations to repair or replace it, according to a new study by Weill Cornell Medicine scientists.

The incidence of metastatic prostate cancer in older men is rising after reaching an all-time low in 2011.